Cerus Corp (Cerus) is a biomedical products company that focuses on the field of blood transfusion safety. It develops and commercializes the Intercept blood system, which reduces the risk of transfusion-transmitted infections by inactivating a wide range of pathogens including viruses, bacteria, and parasites present in donated blood. The Intercept blood system is for use with blood components including platelets, plasma, and red blood cells. It is also used to produce intercept fibrinogen complex (IFC), and pathogen reduced plasma and cryoprecipitate. The company markets and sells the Intercept blood system through its direct sales force and distributors in several countries including the US, Europe, the Commonwealth of Independent States (CIS), Latin America, the Middle East, and selected countries in other regions. Cerus is headquartered in Concord, California, the US.
This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
Scope:
- The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
- The report analyzes all pipeline products in development for the company Cerus Corp
- The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
- The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
- The report provides detailed description of products in development, technical specification and functions
- The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design, trial status and phase, estimated start and end date.
Reasons to Buy:
- Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
- Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
- To formulate effective Research & Development strategies
- Develop market-entry and market expansion strategies
- Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
- Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio
Note: Some sections may be missing if data is unavailable for the company
Table of Contents
- Cerus Corp Company Overview
- Cerus Corp Company Snapshot
- Cerus Corp Pipeline Products and Ongoing Clinical Trials Overview
- Cerus Corp - Pipeline Analysis Overview
- Business Description
- Cerus Corp - Key Facts
- Cerus Corp - Major Products and Services
- Cerus Corp Pipeline Products by Development Stage
- Cerus Corp Ongoing Clinical Trials by Trial Status
- Cerus Corp Pipeline Products Overview
- INTERCEPT Blood System - Platelets
- INTERCEPT Blood System - Platelets Product Overview
- INTERCEPT Blood System - Red Blood Cells
- INTERCEPT Blood System - Red Blood Cells Product Overview
- INTERCEPT Blood System - Red Blood Cells Clinical Trial
- INTERCEPT Blood System - Whole Blood
- INTERCEPT Blood System - Whole Blood Product Overview
- LyoCryo
- LyoCryo Product Overview
- Next Generation INTERCEPT Blood System
- Next Generation INTERCEPT Blood System Product Overview
- Cerus Corp - Key Competitors
- Cerus Corp - Key Employees
- Cerus Corp - Key Employee Biographies
- Cerus Corp - Locations And Subsidiaries
- Head Office
- Other Locations & Subsidiaries
- Recent Developments
- Cerus Corp, Recent Developments
- Mar 26, 2024: Cerus Announces FDA Approval of Extended Shelf Life for Intercept Platelet Processing Sets - Doubling Previous Shelf Life
- Mar 20, 2024: Cerus announces positive results in blood purification trial
- Feb 26, 2024: Growing Demand for Cerus’ INTERCEPT Pathogen Inactivation System for Plasma Drives Additional Investment in Microsize’s Particle Sizing Services.
- Nov 01, 2023: Bloodbuy Announces Agreement With Cerus Corporation to Offer Pathogen Reduced Cryoprecipitated Fibrinogen Complex on Its Digital Marketplace
- Nov 01, 2023: Bloodbuy Announces Agreement with Cerus Corporation to Offer Pathogen Reduced Cryoprecipitated Fibrinogen Complex on its Digital Marketplace
- Oct 10, 2023: Cerus Announces Workshop and Abstracts at the 2023 AABB Annual Meeting
- Sep 27, 2023: Cerus Corp. Announces the Appointment of Alicia Goodman as New Chief Human Resources Officer
- Jun 05, 2023: Cerus Corporation announces follow-on award of U.S. Department of Defense funding for development of pathogen reduced, Lyophilized Cryoprecipitate
- Jan 09, 2023: Cerus Announces Preliminary Fourth Quarter and Full-Year 2022 Product Revenue and Provides Business Update
- Nov 02, 2022: Cerus announces award of U.S. Department of Defense Funding for development of Pathogen Reduced, Lyophilized Cryoprecipitate
- Appendix
- Methodology
- About the Analyst
- Contact the Publisher
- Disclaimer
- Cerus Corp Pipeline Products and Ongoing Clinical Trials Overview
- Cerus Corp Pipeline Products by Equipment Type
- Cerus Corp Pipeline Products by Indication
- Cerus Corp Ongoing Clinical Trials by Trial Status
- Cerus Corp, Key Facts
- Cerus Corp, Major Products and Services
- Cerus Corp Number of Pipeline Products by Development Stage
- Cerus Corp Pipeline Products Summary by Development Stage
- Cerus Corp Ongoing Clinical Trials by Trial Status
- Cerus Corp Ongoing Clinical Trials Summary
- INTERCEPT Blood System - Platelets - Product Status
- INTERCEPT Blood System - Platelets - Product Description
- INTERCEPT Blood System - Red Blood Cells - Product Status
- INTERCEPT Blood System - Red Blood Cells - Product Description
- INTERCEPT Blood System - Red Blood Cells - A Randomized, Double-blinded, Controlled, Parallel Group, Non-inferiority, Phase III Study to Evaluate the Efficacy and Safety of the INTERCEPT Blood System for Red Blood Cells in Patients Undergoing Complex Cardiac Surgery Procedures
- INTERCEPT Blood System - Red Blood Cells - Randomized, Double-blind, Controlled, Parallel Group Study with the INTERCEPT Blood System for RBCs in Regions at Potential Risk for Zika Virus Transfusion-transmitted Infections and Treatment Use Open-label Extension Study
- INTERCEPT Blood System - Whole Blood - Product Status
- INTERCEPT Blood System - Whole Blood - Product Description
- LyoCryo - Product Status
- LyoCryo - Product Description
- Next Generation INTERCEPT Blood System - Product Status
- Next Generation INTERCEPT Blood System - Product Description
- Cerus Corp, Key Employees
- Cerus Corp, Key Employee Biographies
- Cerus Corp, Subsidiaries
- Glossary
- Cerus Corp Pipeline Products by Equipment Type
- Cerus Corp Pipeline Products by Development Stage
- Cerus Corp Ongoing Clinical Trials by Trial Status
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Octapharma AG
- MacoPharma International Gmbh
- Kedrion Biopharma Inc
- Terumo BCT Inc
- Grifols SA
